[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genetic-change\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genetic-change":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,79,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100469866","liver-transplantation-for-non-resectable-colorectal-liver-metastases-translational-research-100469866",false,"NCT05398380","Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research","Clinical Impact of Molecular Biomarkers in Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Male or female, aged 18-70 years old inclusive at study entry.\n3. ECOG (Eastern Cooperative Oncology Group) 0 or 1.\n4. Histologically-proven primary colorectal tumor.\n5. Bilateral, limited at liver and non-resectable CRLM by consensus in Multidisciplinary Committee.\n6. Resection of primary colorectal tumor according oncological principles and adequate TNM stage.\n7. Time from primary colorectal tumor resection to transplant ≥ 12 months.\n8. Primary colorectal tumor stage ≤ T3N1. If time between primary tumor resection is ≥ 2 years, stage T4N0 or T4N2 is accepted.\n9. No signs of extrahepatic metastatic disease according to PET\u002FCT scan, CT and pelvic MRI.\n10. The patient has undergone systemic chemotherapy for a minimum of 3 months at the time of screening and maximum of 2 lines of fluoropyrimidine based chemotherapy combined or not with irinotecan or oxaliplatin associated or no not with targeted therapy based in molecular biomarkers.\n11. Demonstrated stability or partial regression of CRLM following RECIST criteria v 1.1., at minimum 3 months since the last treatment received and immediately prior to screening.\n12. CEA (Carcinoembryonic antigen) values ≤ 80 µg\u002FL immediately prior to screening.\n13. Adequate blood test regarding:\n\n    * Creatinine ≤1.25 x upper normal level or estimated glomerular filtration rate (eGFR) ≥60 mL\u002Fmin\u002F1.73m2 using following the Chronic Kidney disease epidemiology collaboration (CKD-EPI) formula.\n    * Platelets ≥80 × 109\u002FL\n    * Neutrophiles ≥ 2.5 × 109\u002FL\n14. Patients with hepatic failure after resection will be considered if it occurs as a consequence of an inadequate preoperative estimation of the functional volume that would have contraindicated the surgery. They should meet the inclusion criteria and none of the exclusion criteria.\n\nExclusion Criteria:\n\n1. Largest Lesion \\>5.5cm immediately prior to screening\n2. Patients with Lynch Syndrome\n3. BRAF mutation and\u002For primary tumor of microsatellite instability (MSI)\n4. Recurrence of primary tumor confirmed by colonoscopy or pelvic MRI within the last 12 months prior to screening.\n5. Previous or concurrent cancer in the last 5 years. Any cancer curatively treated 5 years prior to entry or treated basal cell carcinoma is permitted.\n6. Substance abuse, medical, psychological or social conditions that may interfere with the patient´s participation in the study or evaluation of the study results.\n7. Cardiac or pulmonary disease uncontrolled as contraindication for any surgical procedure.\n8. Active infection.\n9. Pregnant or breast-feeding patients\n10. Any reason why in the opinion of the investigator, the patient should not participate.","ALL","18 Years","70 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","The patients with non-resectable colorectal liver metastases (CRLM) have always being considered a particular subgroup of CRLM in which the therapeutic approach, is focused on strategies that allow a potential surgery like neoadjuvant systemic treatments. But, the underlying biology that causes this particular profile of spread in a proportion of patients that always recur and progress in the liver has not been properly characterized from a biological point of view. Unfortunately, these patients finally develop liver metastasis not amenable for local treatments and become refractory to systemic treatments even without developing extrahepatic liver metastases. As a result, liver transplantation (LT) is a potential for patients without extrahepatic involvement and nonresectable CRLM. There are several studies that aims to evaluate if LT increases overall survival compared to best alternative care. To our knowledge, none of these studies incorporate objectives focused on the underlying tumor biology of this particular population and the development of focused strategies including a dynamic disease monitoring and targeted treatments for this particular population.The METLIVER trial will permit to expand the genetic studies to the whole complexity of metastatic lesions and a more precise evaluation of their genetic heterogeneity. Moreover, it will help to precise the type of genetic analyses on liquid biopsies that can be designed for patients that will unfortunately relapse mostly with lung metastases after LT. Our proposal will maximize the opportunity to produce an unprecedented knowledge on CRLM evolution and will provide new opportunities for relapsed patients.",[27,28,29],"Colorectal Cancer","Liver Metastases","Genetic Change",[31,32,33,34],"Liver Transplantation","Non-resectable colorectal liver metastases","Tumoral biomarkers","Translational research","RECRUITING","2026-05-21",{"date":38,"type":39},"2026-05-22","ACTUAL",{"date":41,"type":39},"2022-01-01",{"date":43,"type":21},"2026-12-31",{"name":45,"class":46},"Hospital Vall d'Hebron","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100622654","the-association-between-deep-endometriosis-and-the-occurrence-of-colorectal-carcinoma-100622654","NCT07386431","The Association Between Deep Endometriosis and the Occurrence of Colorectal Carcinoma","Inclusion Criteria:\n\nFemale patients aged 18 and over, treated at the Department of Reproduction for diagnosed deep endometriosis, including bowel endometriosis, for whom surgical treatment is indicated.\n\nExclusion Criteria:\n\n* Patients with known inflammatory bowel disease (IBD), patients with a personal history of gynecological or gastrointestinal malignancy","FEMALE",{"count":56,"type":21},30,"OBSERVATIONAL","The goal of this study is to identify the molecular or genetic mechanisms that may predispose patients with bowel endometriosis to an increased risk of colorectal carcinoma. The study will include patients for whom surgical treatment of bowel endometriosis is clinically indicated.\n\nThis research would represent a significant advancement in evaluating the necessity of surgical intervention in asymptomatic patients or those with mild symptoms. Furthermore, it would provide a broader insight into the systemic impact of endometriosis on other organ systems, ultimately improving risk assessment and preventive measures.",[60,61,62,63,64,65,66,67,29,68],"Endometriosis","Deep Endometriosis","Bowel Endometriosis","Colorectal Carcinoma","Colon Resection","Endometriosis Pelvic","Endometriosis Rectum","Carcinogenesis","Infertility","NOT_YET_RECRUITING","2026-02-05",{"date":72,"type":39},"2026-02-06",{"date":74,"type":21},"2026-02",{"date":76,"type":21},"2029-05",{"name":78,"class":46},"University Medical Centre Ljubljana",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":16,"minAge":87,"maxAge":17,"enrollmentInfo":88,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100575868","comt-and-oprm1-polymorphisms-and-their-effect-on-post-operative-pain-in-children-100575868","NCT06777875","COMT and OPRM1 Polymorphisms and Their Effect on Post-Operative Pain in Children","COMT and OPRM1 Polymorphisms and Their Effect on Post-Operative Pain in Children Undergoing Orthopedic, Abdominal, Thoracic, and Plastic Surgeries.","Inclusion Criteria:\n\n* All children 8 years to 18 years\n* Undergoing orthopedic, abdominal, thoracic, and plastic surgeries\n* American Society of Anesthesiologists classification (ASA) I-II-III\n\nExclusion Criteria:\n\n* Children with schizoid personality disorders, phobias, and anxiety\n* Patients with neuropathic pain associated with surgeries requiring surgical treatment.\n* Children presented with all types of depressive disorders, atypical bipolar disorder, or a suspicion of substance abuse.\n* American Society of Anesthesiologists classification (ASA) ≥IV\n* All patients receiving regional anesthesia, local blocks, epidural and caudal blocks.",true,"8 Years",{"count":89,"type":21},200,"The goal of this observational study is to investigate whether the A118G single-nucleotide polymorphism (SNP) in the mu-opioid receptor1(OPRM1) and Catechol-O-methyltransferase (COMT) SNPs influence postoperative pain scores in children between the ages of 8 and 18 undergoing orthopedic, abdominal, thoracic, and plastic surgeries.\n\nThe main question\\[s\\] it aims to answer \\[is\\]:\n\nDo OPRM1 and COMT SNPs influence postoperative pain scores in children between the ages of 8 and 18 undergoing orthopedic, abdominal, thoracic, and plastic surgeries?\n\nParticipants will be assessed for their pain scores, sedation level, the amount of postoperative analgesics received, duration of their stay in the post-anesthesia care unit, and toxicity.",[92,29,93],"Pain","Children, Only","2025-03-14",{"date":96,"type":39},"2025-03-18",{"date":98,"type":39},"2025-03-10",{"date":100,"type":21},"2027-01-13",{"name":102,"class":46},"American University of Beirut Medical Center",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":113,"studyType":57,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":47},"100478619","study-on-gene-evolution-in-glioma-under-stress-therapy-100478619","NCT05512325","Study on Gene Evolution in Glioma Under Stress Therapy","Study on Gene Evolution and Anti-VEGF Treatment Response of Different Subtypes of Glioma Based on ctDNA","Inclusion Criteria:\n\n* Age 18 to 75 years, both male and female (including 18 and 75 years old) glioma;\n* Willing to accept treatment and sign informed consent.\n\nExclusion Criteria:\n\n* Participants with other infection disease or immunodeficiency disease;\n* other central infectious diseases;\n* malignant tumor of non-nervous system;\n* drug abuse;\n* severe psychiatric disease;\n* uncontrolled diabetes;","75 Years",{"count":112,"type":21},100,"5 Years","Little is known about the evolution of genetic and epigenetic changes that occur in the progression of glioma. We inferred the evolution trajectories of matched pairs of primary tumors and progression tumor in situ fluid (TISF) based on deep whole-genome-sequencing data (ctDNA). A monocentric, Gene grouping controlled trial design was used to select patients. and to compare gene evolution of different subtypes of glioma under therapy. To predict the molecular reaction of bevacizumab treatment, clarify the mechanism of drug resistance of bevacizumab treatment.",[29],[117],"gene evolution, ctDNA, molecular response, Bevacizumab","2022-09-25",{"date":120,"type":39},"2022-09-27",{"date":122,"type":21},"2022-12-17",{"date":43,"type":21},{"name":125,"class":46},"Henan Provincial People's Hospital"]